Latest / Stock Picking with Fexingo: Individual Equities, Research, and Building a Concentrated Portfolio
Why Pfizer Is Quietly Becoming an Income Play
When you think of Pfizer, you probably think of the COVID vaccine wild ride—a stock that surged, then cratered, then became an afterthought. But in this episode of Stock Picking with Fexingo, Lucas and Luna dig into the Pfizer that exists today: a company with a 5.9% dividend yield, a pipeline that's actually delivering, and a valuation that income investors can't ignore. They walk through the math behind the yield, the case for the oncology pipeline, and why the market might be pricing in too much pessimism. Plus, they contrast Pfizer's risk profile with a stock like Chevron…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.